跳至主要内容
临床试验/IRCT2016010225812N1
IRCT2016010225812N1已完成2 期

Evaluation the efficacy of Raloxifine and Isradipine in cognitive impairment of schizophrenic patients

Vice Chancellor for Research of Zanjan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Inclusion Criteria: All enrolled patients will have normal IQ ; systolic blood pressure more than 100 mmHg ; diastolic blood pressure more than 60 mmHg ; at least 2 years diagnosis of schizophrenia or schizoaffective disorder according to DSM-V diagnostic criteria.

排除标准

  • patients with any other comorbidity of psychiatric or neurologic disorders ; history of lifetime substance abuse ; any sensitivity to drugs ; history of head trauma or loss of consciousness ; resistant high blood pressure ; resistance in treatment of schizophrenia or beginning Clozapine ; renal, liver or cardiac failure ; women' s pregnancy or breast feeding ; any abnormality in ECG ; suicide idea ; history of dementia ; breast cancer ; tromboemboli events ; dementia ; endocrine disease ; history of receiving ECT during last 12 months.

研究者

发起方
Vice Chancellor for Research of Zanjan University of Medical Sciences

相似试验